Brace Pharma Capital leads $33 mln Series B funding in Navitor

Brace Pharma Capital led a $33 million Series B funding in Navitor Pharmaceuticals, a biopharmaceutical company. Other investors in the funding included Remeditex Ventures, Sanofi-Genzyme BioVentures and an undisclosed individual investor. Existing investors Polaris Partners, Atlas Venture, Johnson & Johnson Innovation and SR One also participated. Vinzenz Ploerer, president and chief executive officer of Brace Pharma Capital, will join Navitor's board.

North AmericaUSBriefs